Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02151318|
Recruitment Status : Unknown
Verified June 2015 by University of South Florida.
Recruitment status was: Recruiting
First Posted : May 30, 2014
Last Update Posted : June 26, 2015
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||May 2016|
|Estimated Study Completion Date :||August 2016|
- Efficacy of new glaucoma medications to reduce TM cellular pathologies associated with the disease glaucoma. [ Time Frame: 6 weeks ]TM cell biopsy samples from patients with glaucoma will be harvested and cultured in a laboratory setting to grow primary human TM cells. These cells will be used to test different medications, looking at the medications ability to reduce cellular pathologies commonly seen in TM tissue of patients with glaucoma. Pathologies include myocilin aggregation, and cell death. This will help researchers to determine the most effective compounds in treating glaucoma.
- Cultured TM cell toxicity caused by new glaucoma medications [ Time Frame: 6 weeks ]Cultured primary TM cells treated with various new medications synthesized to treat cellular pathologies associated with glaucoma, will also be analyzed to look at toxicity caused by the treatments themselves. THis will help to determine the safety of these new medications prior to being administered to patients.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02151318
|United States, Florida|
|Tampa General Hosipital||Recruiting|
|Tampa, Florida, United States, 33606|
|Contact: Carla Bourne, MD 813-974-5853 email@example.com|
|Principal Investigator: Carla Bourne, MD|
|Byrd Alzheimer's Institute||Recruiting|
|Tampa, Florida, United States, 33613|
|Contact: Chad A Dickey, PhD 813-396-0639 firstname.lastname@example.org|
|Principal Investigator: Chad A Dickey, PhD|
|Sub-Investigator: Andrew R Stothert, MS|
|Principal Investigator:||Chad A Dickey, PhD||University of South Florida department of Molecular Medicine and Byrd Alzheimer's Institute|
|Study Director:||Carla Bourne, MD||University of South Florida and Tampa General Hospital|